DOUBLE-EXPRESSOR LYMPHOMA
Clinical trials for DOUBLE-EXPRESSOR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new DOUBLE-EXPRESSOR LYMPHOMA trials appear
Sign up with your email to follow new studies for DOUBLE-EXPRESSOR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to stop aggressive lymphomas from coming back
Disease control OngoingThis study tests whether adding the drug venetoclax to standard chemotherapy can keep high-grade B-cell lymphomas from returning or getting worse. About 363 adults with these aggressive lymphomas will receive either the usual chemo or the usual chemo plus venetoclax. The goal is …
Matched conditions: DOUBLE-EXPRESSOR LYMPHOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 09:10 UTC
-
Promising combo tackles tough lymphoma
Disease control OngoingThis study tests a new drug combination for people with aggressive types of B-cell lymphoma that haven't been treated yet. The treatment adds a targeted drug called polatuzumab vedotin to standard chemotherapy. The goal is to see if this combo can make the cancer disappear comple…
Matched conditions: DOUBLE-EXPRESSOR LYMPHOMA
Phase: PHASE2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated May 12, 2026 13:39 UTC